14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
LLY vs AKRO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Eli Lilly & Co. (LLY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LLY carries a Unified Composite Score of 41.4/100 (SELL) at $1,347.11 (26.5x Forward P/E, 51.2% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. LLY 41.4/100 SELL), LLY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (51.2% vs. 0.0% operating margin) and revenue trajectory (+38.6% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LLY vs AKRO. Trailing 12-month operating profitability (LLY 51.2% vs AKRO 0.0%) and valuation multiples (LLY 26.5x vs AKRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LLY vs AKRO Key Questions & Quantitative Answers
As of Nov 20, 2026, Eli Lilly & Co. (LLY) is the stronger overall head-to-head candidate over Akero Therapeutics, Inc. (AKRO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LLY carries a Unified Composite Score of 41.4/100 (SELL) at $1,347.11 (26.5x Forward P/E, 51.2% operating margin), whereas AKRO carries 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AKRO currently prints a higher short-term Unified Composite Score (60.0/100 BUY vs. LLY 41.4/100 SELL), LLY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (51.2% vs. 0.0% operating margin) and revenue trajectory (+38.6% vs. +0.0% YoY).
LLY leads the Growth & Scale pillar: LLY posts +38.6% YoY revenue growth and +16.3% YoY earnings growth on $86.5B TTM revenue (83.6% gross margin, 51.2% operating margin), compared with AKRO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, LLY generates $86.5B in USD-normalized revenue versus N/A for AKRO. In operating R&D and SG&A reinvestment, LLY deploys 32.4% of Rev ($28.0B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AKRO.
LLY screens cheaper on headline valuation multiples. LLY trades at 26.5x Forward P/E, 44.9x Trailing P/E, 1.28x PEG, and 14.4x EV/Revenue (13.5% FCF margin), whereas AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LLY (86.0% ROE) versus AKRO (-34.5% ROE) capital efficiency.
In options market volatility and institutional positioning, LLY carries 34.2% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.95x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.32β · 36% Vol realized risk). By comparison, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.